The $45m facility focuses on identifying and developing products that meet the needs of China and other markets as well as discovering new platforms in medical technology.
Covidien president, CEO and chairman Jose Almeida said, "Establishing this R&D facility in Shanghai reinforces Covidien’s continued commitment to providing innovative new products that will help healthcare providers worldwide improve patient care and extend healthcare delivery to more people and more places."
Covidien R&D vice president Dong Wu said by collaborating closely with local medical experts who use the company’s products, it can tailor devices to meet the demands of China and other markets.
"This location will help us tap into internationally renowned experts based here in China, including world-class engineering talent," Wu added.
"This fusion of expertise among healthcare professionals, students, scientists and engineers will be further reinforced by the cutting-edge capabilities of our new R&D facility, bridging clinical knowledge, market understanding and technical innovation."